Physician profile
Ashley D Mcintyre
NPI 1699747709
$123,176.68
in general payments reported to CMS, 2019-2025
62 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,297 · 2020: $22K · 2021: $22K · 2022: $20K · 2023: $14K · 2024: $21K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Food and Beverage: $3,903 · Travel and Lodging: $2,576 · Education: $82.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,599.19 |
| Food and Beverage | $3,902.84 |
| Travel and Lodging | $2,576.27 |
| Education | $82.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $90,403.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,962.20 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $7,551.82 | 2019-2025 | Jardiance, Mounjaro |
| Esperion Therapeutics, INC. | $2,840.60 | 2020-2022 | |
| Amarin Pharma, INC. | $1,362.54 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,086.80 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $1,036.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $788.64 | 2019-2025 | Verquvo |
| Abbvie INC. | $569.05 | 2020-2025 | |
| Amgen INC. | $512.94 | 2019-2025 | Krystexxa, Repatha |
| Corcept Therapeutics | $449.75 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $424.61 | 2019-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $360.45 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $349.81 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.71 | 2019-2023 | Xifaxan |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mcintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.